nodes	percent_of_prediction	percent_of_DWPC	metapath
Theophylline—SLC22A7—Fluorouracil—urinary bladder cancer	0.1	0.229	CbGbCtD
Theophylline—CYP1B1—Doxorubicin—urinary bladder cancer	0.063	0.144	CbGbCtD
Theophylline—SLC22A7—Methotrexate—urinary bladder cancer	0.0552	0.126	CbGbCtD
Theophylline—PDE5A—clitoris—urinary bladder cancer	0.0386	0.224	CbGeAlD
Theophylline—CYP3A4—Thiotepa—urinary bladder cancer	0.035	0.0799	CbGbCtD
Theophylline—CYP2E1—Etoposide—urinary bladder cancer	0.0313	0.0715	CbGbCtD
Theophylline—CYP2C8—Fluorouracil—urinary bladder cancer	0.028	0.064	CbGbCtD
Theophylline—CYP2C8—Etoposide—urinary bladder cancer	0.0234	0.0534	CbGbCtD
Theophylline—CYP1A2—Fluorouracil—urinary bladder cancer	0.0217	0.0495	CbGbCtD
Theophylline—CYP2C9—Fluorouracil—urinary bladder cancer	0.0195	0.0446	CbGbCtD
Theophylline—CYP1A2—Etoposide—urinary bladder cancer	0.0181	0.0413	CbGbCtD
Theophylline—CYP2C9—Cisplatin—urinary bladder cancer	0.0166	0.0379	CbGbCtD
Theophylline—PDE5A—penis—urinary bladder cancer	0.0109	0.0636	CbGeAlD
Theophylline—PDE3A—penis—urinary bladder cancer	0.0107	0.0618	CbGeAlD
Theophylline—CYP2D6—Doxorubicin—urinary bladder cancer	0.0102	0.0232	CbGbCtD
Theophylline—CYP3A4—Etoposide—urinary bladder cancer	0.00948	0.0217	CbGbCtD
Theophylline—CYP3A4—Doxorubicin—urinary bladder cancer	0.00647	0.0148	CbGbCtD
Theophylline—Caffeine—ATM—urinary bladder cancer	0.00584	1	CrCbGaD
Theophylline—PDE3B—prostate gland—urinary bladder cancer	0.00416	0.0242	CbGeAlD
Theophylline—PDE4D—prostate gland—urinary bladder cancer	0.00348	0.0202	CbGeAlD
Theophylline—ADORA2B—prostate gland—urinary bladder cancer	0.00345	0.02	CbGeAlD
Theophylline—HDAC2—Teniposide—Etoposide—urinary bladder cancer	0.00321	1	CbGdCrCtD
Theophylline—ADA—prostate gland—urinary bladder cancer	0.00316	0.0183	CbGeAlD
Theophylline—CYP1A2—urine—urinary bladder cancer	0.00314	0.0182	CbGeAlD
Theophylline—PDE4A—prostate gland—urinary bladder cancer	0.00308	0.0179	CbGeAlD
Theophylline—CYP2C9—urine—urinary bladder cancer	0.00298	0.0173	CbGeAlD
Theophylline—CYP2E1—urine—urinary bladder cancer	0.00282	0.0164	CbGeAlD
Theophylline—PDE5A—prostate gland—urinary bladder cancer	0.00262	0.0152	CbGeAlD
Theophylline—PDE3A—prostate gland—urinary bladder cancer	0.00254	0.0148	CbGeAlD
Theophylline—HDAC2—prostate gland—urinary bladder cancer	0.00245	0.0142	CbGeAlD
Theophylline—ADORA2B—smooth muscle tissue—urinary bladder cancer	0.00244	0.0142	CbGeAlD
Theophylline—ADORA2B—urethra—urinary bladder cancer	0.00231	0.0134	CbGeAlD
Theophylline—CYP3A4—urine—urinary bladder cancer	0.00227	0.0132	CbGeAlD
Theophylline—CYP2D6—urine—urinary bladder cancer	0.00224	0.013	CbGeAlD
Theophylline—ADA—renal system—urinary bladder cancer	0.00215	0.0125	CbGeAlD
Theophylline—SLC22A7—renal system—urinary bladder cancer	0.00194	0.0113	CbGeAlD
Theophylline—PDE5A—epithelium—urinary bladder cancer	0.00192	0.0112	CbGeAlD
Theophylline—PDE5A—smooth muscle tissue—urinary bladder cancer	0.00185	0.0107	CbGeAlD
Theophylline—PDE4B—prostate gland—urinary bladder cancer	0.00183	0.0106	CbGeAlD
Theophylline—PDE3A—smooth muscle tissue—urinary bladder cancer	0.0018	0.0105	CbGeAlD
Theophylline—HDAC2—epithelium—urinary bladder cancer	0.0018	0.0104	CbGeAlD
Theophylline—PDE5A—renal system—urinary bladder cancer	0.00178	0.0103	CbGeAlD
Theophylline—PDE5A—urethra—urinary bladder cancer	0.00175	0.0102	CbGeAlD
Theophylline—HDAC2—smooth muscle tissue—urinary bladder cancer	0.00173	0.0101	CbGeAlD
Theophylline—ADA—female reproductive system—urinary bladder cancer	0.00172	0.01	CbGeAlD
Theophylline—ADORA2B—vagina—urinary bladder cancer	0.0017	0.00989	CbGeAlD
Theophylline—ADORA1—renal system—urinary bladder cancer	0.00169	0.00981	CbGeAlD
Theophylline—HDAC2—renal system—urinary bladder cancer	0.00167	0.00969	CbGeAlD
Theophylline—ADORA1—urethra—urinary bladder cancer	0.00166	0.00964	CbGeAlD
Theophylline—CYP1B1—prostate gland—urinary bladder cancer	0.00157	0.00912	CbGeAlD
Theophylline—ADORA2A—female reproductive system—urinary bladder cancer	0.00157	0.0091	CbGeAlD
Theophylline—ADA—vagina—urinary bladder cancer	0.00156	0.00905	CbGeAlD
Theophylline—PDE5A—female reproductive system—urinary bladder cancer	0.00143	0.00829	CbGeAlD
Theophylline—PDE3A—female reproductive system—urinary bladder cancer	0.00139	0.00806	CbGeAlD
Theophylline—ADORA1—female reproductive system—urinary bladder cancer	0.00135	0.00786	CbGeAlD
Theophylline—HDAC2—female reproductive system—urinary bladder cancer	0.00134	0.00776	CbGeAlD
Theophylline—PDE3B—lymph node—urinary bladder cancer	0.00133	0.00772	CbGeAlD
Theophylline—PDE5A—vagina—urinary bladder cancer	0.00129	0.0075	CbGeAlD
Theophylline—PDE4B—urethra—urinary bladder cancer	0.00123	0.00713	CbGeAlD
Theophylline—ADORA1—vagina—urinary bladder cancer	0.00122	0.00711	CbGeAlD
Theophylline—HDAC2—vagina—urinary bladder cancer	0.00121	0.00702	CbGeAlD
Theophylline—CYP1B1—smooth muscle tissue—urinary bladder cancer	0.00111	0.00646	CbGeAlD
Theophylline—PDE4D—lymph node—urinary bladder cancer	0.00111	0.00644	CbGeAlD
Theophylline—CYP1B1—renal system—urinary bladder cancer	0.00107	0.00622	CbGeAlD
Theophylline—CYP2E1—prostate gland—urinary bladder cancer	0.00101	0.00588	CbGeAlD
Theophylline—ADA—lymph node—urinary bladder cancer	0.00101	0.00585	CbGeAlD
Theophylline—PDE4B—female reproductive system—urinary bladder cancer	0.001	0.00581	CbGeAlD
Theophylline—PDE4A—lymph node—urinary bladder cancer	0.000982	0.0057	CbGeAlD
Theophylline—PDE4B—vagina—urinary bladder cancer	0.000905	0.00526	CbGeAlD
Theophylline—CYP1B1—female reproductive system—urinary bladder cancer	0.000858	0.00498	CbGeAlD
Theophylline—CYP2E1—seminal vesicle—urinary bladder cancer	0.000857	0.00498	CbGeAlD
Theophylline—PDE5A—lymph node—urinary bladder cancer	0.000835	0.00485	CbGeAlD
Theophylline—CYP2C8—renal system—urinary bladder cancer	0.00082	0.00476	CbGeAlD
Theophylline—CYP1A1—epithelium—urinary bladder cancer	0.000816	0.00474	CbGeAlD
Theophylline—PDE3A—lymph node—urinary bladder cancer	0.000812	0.00472	CbGeAlD
Theophylline—ADORA1—lymph node—urinary bladder cancer	0.000792	0.0046	CbGeAlD
Theophylline—HDAC2—lymph node—urinary bladder cancer	0.000782	0.00454	CbGeAlD
Theophylline—CYP1A2—renal system—urinary bladder cancer	0.000768	0.00446	CbGeAlD
Theophylline—CYP1A1—renal system—urinary bladder cancer	0.000757	0.0044	CbGeAlD
Theophylline—Haematemesis—Epirubicin—urinary bladder cancer	0.000755	0.00431	CcSEcCtD
Theophylline—Hypercalcaemia—Epirubicin—urinary bladder cancer	0.000755	0.00431	CcSEcCtD
Theophylline—Irritability—Fluorouracil—urinary bladder cancer	0.000746	0.00426	CcSEcCtD
Theophylline—CYP1A1—urethra—urinary bladder cancer	0.000744	0.00432	CbGeAlD
Theophylline—Hyperglycaemia—Thiotepa—urinary bladder cancer	0.000737	0.00421	CcSEcCtD
Theophylline—Body temperature increased—Mitomycin—urinary bladder cancer	0.00073	0.00417	CcSEcCtD
Theophylline—Hypokalaemia—Gemcitabine—urinary bladder cancer	0.000724	0.00413	CcSEcCtD
Theophylline—Ventricular arrhythmia—Epirubicin—urinary bladder cancer	0.000709	0.00404	CcSEcCtD
Theophylline—Irritability—Cisplatin—urinary bladder cancer	0.000708	0.00404	CcSEcCtD
Theophylline—Albuminuria—Epirubicin—urinary bladder cancer	0.000702	0.00401	CcSEcCtD
Theophylline—Anaphylactoid reaction—Etoposide—urinary bladder cancer	0.000702	0.00401	CcSEcCtD
Theophylline—Haematemesis—Doxorubicin—urinary bladder cancer	0.000698	0.00399	CcSEcCtD
Theophylline—Hypercalcaemia—Doxorubicin—urinary bladder cancer	0.000698	0.00399	CcSEcCtD
Theophylline—Haematuria—Thiotepa—urinary bladder cancer	0.000695	0.00397	CcSEcCtD
Theophylline—CYP2E1—renal system—urinary bladder cancer	0.000691	0.00401	CbGeAlD
Theophylline—CYP2E1—urethra—urinary bladder cancer	0.000678	0.00394	CbGeAlD
Theophylline—Hypokalaemia—Cisplatin—urinary bladder cancer	0.000675	0.00385	CcSEcCtD
Theophylline—CYP2C8—female reproductive system—urinary bladder cancer	0.000657	0.00381	CbGeAlD
Theophylline—Ventricular arrhythmia—Doxorubicin—urinary bladder cancer	0.000656	0.00374	CcSEcCtD
Theophylline—Albuminuria—Doxorubicin—urinary bladder cancer	0.00065	0.00371	CcSEcCtD
Theophylline—Extravasation—Methotrexate—urinary bladder cancer	0.000642	0.00367	CcSEcCtD
Theophylline—Diarrhoea—Mitomycin—urinary bladder cancer	0.000632	0.00361	CcSEcCtD
Theophylline—Hyperglycaemia—Gemcitabine—urinary bladder cancer	0.00062	0.00354	CcSEcCtD
Theophylline—Dizziness—Mitomycin—urinary bladder cancer	0.000611	0.00349	CcSEcCtD
Theophylline—CYP1A1—female reproductive system—urinary bladder cancer	0.000607	0.00352	CbGeAlD
Theophylline—Hyperuricaemia—Methotrexate—urinary bladder cancer	0.000604	0.00345	CcSEcCtD
Theophylline—Extravasation—Epirubicin—urinary bladder cancer	0.000601	0.00343	CcSEcCtD
Theophylline—CYP2C8—vagina—urinary bladder cancer	0.000594	0.00345	CbGeAlD
Theophylline—Vomiting—Mitomycin—urinary bladder cancer	0.000587	0.00335	CcSEcCtD
Theophylline—PDE4B—lymph node—urinary bladder cancer	0.000586	0.0034	CbGeAlD
Theophylline—Haematuria—Gemcitabine—urinary bladder cancer	0.000584	0.00334	CcSEcCtD
Theophylline—Arrhythmia—Thiotepa—urinary bladder cancer	0.000584	0.00334	CcSEcCtD
Theophylline—CYP2C9—female reproductive system—urinary bladder cancer	0.000584	0.00339	CbGeAlD
Theophylline—Rash—Mitomycin—urinary bladder cancer	0.000583	0.00333	CcSEcCtD
Theophylline—Dermatitis—Mitomycin—urinary bladder cancer	0.000582	0.00332	CcSEcCtD
Theophylline—Ventricular extrasystoles—Epirubicin—urinary bladder cancer	0.000581	0.00331	CcSEcCtD
Theophylline—Headache—Mitomycin—urinary bladder cancer	0.000579	0.0033	CcSEcCtD
Theophylline—Alopecia—Thiotepa—urinary bladder cancer	0.000578	0.0033	CcSEcCtD
Theophylline—Blood uric acid increased—Methotrexate—urinary bladder cancer	0.000571	0.00326	CcSEcCtD
Theophylline—Hyperuricaemia—Epirubicin—urinary bladder cancer	0.000565	0.00323	CcSEcCtD
Theophylline—Tension—Thiotepa—urinary bladder cancer	0.000559	0.00319	CcSEcCtD
Theophylline—Extravasation—Doxorubicin—urinary bladder cancer	0.000556	0.00317	CcSEcCtD
Theophylline—CYP3A4—renal system—urinary bladder cancer	0.000556	0.00323	CbGeAlD
Theophylline—CYP2E1—female reproductive system—urinary bladder cancer	0.000553	0.00321	CbGeAlD
Theophylline—Nervousness—Thiotepa—urinary bladder cancer	0.000553	0.00316	CcSEcCtD
Theophylline—Nausea—Mitomycin—urinary bladder cancer	0.000549	0.00313	CcSEcCtD
Theophylline—CYP1A1—vagina—urinary bladder cancer	0.000549	0.00318	CbGeAlD
Theophylline—CYP2D6—renal system—urinary bladder cancer	0.000547	0.00317	CbGeAlD
Theophylline—Ventricular extrasystoles—Doxorubicin—urinary bladder cancer	0.000537	0.00307	CcSEcCtD
Theophylline—Blood uric acid increased—Epirubicin—urinary bladder cancer	0.000534	0.00305	CcSEcCtD
Theophylline—Agitation—Thiotepa—urinary bladder cancer	0.000523	0.00299	CcSEcCtD
Theophylline—Hyperuricaemia—Doxorubicin—urinary bladder cancer	0.000523	0.00299	CcSEcCtD
Theophylline—Dermatitis contact—Epirubicin—urinary bladder cancer	0.000518	0.00296	CcSEcCtD
Theophylline—Coma—Methotrexate—urinary bladder cancer	0.000512	0.00292	CcSEcCtD
Theophylline—CYP1B1—lymph node—urinary bladder cancer	0.000502	0.00291	CbGeAlD
Theophylline—Blood uric acid increased—Doxorubicin—urinary bladder cancer	0.000494	0.00282	CcSEcCtD
Theophylline—Convulsion—Thiotepa—urinary bladder cancer	0.000493	0.00282	CcSEcCtD
Theophylline—Arrhythmia—Gemcitabine—urinary bladder cancer	0.000492	0.00281	CcSEcCtD
Theophylline—Alopecia—Gemcitabine—urinary bladder cancer	0.000486	0.00278	CcSEcCtD
Theophylline—Arrhythmia—Fluorouracil—urinary bladder cancer	0.000483	0.00276	CcSEcCtD
Theophylline—Anxiety—Thiotepa—urinary bladder cancer	0.000483	0.00276	CcSEcCtD
Theophylline—Dermatitis contact—Doxorubicin—urinary bladder cancer	0.00048	0.00274	CcSEcCtD
Theophylline—Coma—Epirubicin—urinary bladder cancer	0.000479	0.00274	CcSEcCtD
Theophylline—Alopecia—Fluorouracil—urinary bladder cancer	0.000478	0.00273	CcSEcCtD
Theophylline—Flushing—Cisplatin—urinary bladder cancer	0.000476	0.00272	CcSEcCtD
Theophylline—Polyuria—Methotrexate—urinary bladder cancer	0.000463	0.00264	CcSEcCtD
Theophylline—Infection—Thiotepa—urinary bladder cancer	0.000462	0.00264	CcSEcCtD
Theophylline—Arrhythmia—Cisplatin—urinary bladder cancer	0.000458	0.00262	CcSEcCtD
Theophylline—Nervous system disorder—Thiotepa—urinary bladder cancer	0.000456	0.0026	CcSEcCtD
Theophylline—Tachycardia—Thiotepa—urinary bladder cancer	0.000454	0.00259	CcSEcCtD
Theophylline—Alopecia—Cisplatin—urinary bladder cancer	0.000453	0.00259	CcSEcCtD
Theophylline—CYP3A4—female reproductive system—urinary bladder cancer	0.000445	0.00258	CbGeAlD
Theophylline—Coma—Doxorubicin—urinary bladder cancer	0.000443	0.00253	CcSEcCtD
Theophylline—Anorexia—Thiotepa—urinary bladder cancer	0.000443	0.00253	CcSEcCtD
Theophylline—Phlebitis—Epirubicin—urinary bladder cancer	0.000442	0.00252	CcSEcCtD
Theophylline—CYP2D6—female reproductive system—urinary bladder cancer	0.000438	0.00254	CbGeAlD
Theophylline—Flushing—Etoposide—urinary bladder cancer	0.000436	0.00249	CcSEcCtD
Theophylline—Dermatitis exfoliative—Methotrexate—urinary bladder cancer	0.000431	0.00246	CcSEcCtD
Theophylline—Anaphylactoid reaction—Methotrexate—urinary bladder cancer	0.00042	0.0024	CcSEcCtD
Theophylline—Tremor—Cisplatin—urinary bladder cancer	0.000418	0.00239	CcSEcCtD
Theophylline—Alopecia—Etoposide—urinary bladder cancer	0.000415	0.00237	CcSEcCtD
Theophylline—Phlebitis—Doxorubicin—urinary bladder cancer	0.000409	0.00233	CcSEcCtD
Theophylline—Convulsion—Fluorouracil—urinary bladder cancer	0.000408	0.00233	CcSEcCtD
Theophylline—Decreased appetite—Thiotepa—urinary bladder cancer	0.000404	0.00231	CcSEcCtD
Theophylline—Dermatitis exfoliative—Epirubicin—urinary bladder cancer	0.000403	0.0023	CcSEcCtD
Theophylline—Anaphylactoid reaction—Epirubicin—urinary bladder cancer	0.000393	0.00225	CcSEcCtD
Theophylline—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.000391	0.00223	CcSEcCtD
Theophylline—Infection—Gemcitabine—urinary bladder cancer	0.000388	0.00222	CcSEcCtD
Theophylline—Irritability—Methotrexate—urinary bladder cancer	0.000388	0.00222	CcSEcCtD
Theophylline—Convulsion—Cisplatin—urinary bladder cancer	0.000387	0.00221	CcSEcCtD
Theophylline—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.000384	0.00219	CcSEcCtD
Theophylline—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.000383	0.00219	CcSEcCtD
Theophylline—Infection—Fluorouracil—urinary bladder cancer	0.000382	0.00218	CcSEcCtD
Theophylline—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.00038	0.00217	CcSEcCtD
Theophylline—Anxiety—Cisplatin—urinary bladder cancer	0.000379	0.00216	CcSEcCtD
Theophylline—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.000377	0.00215	CcSEcCtD
Theophylline—Tachycardia—Fluorouracil—urinary bladder cancer	0.000375	0.00214	CcSEcCtD
Theophylline—Dermatitis exfoliative—Doxorubicin—urinary bladder cancer	0.000373	0.00213	CcSEcCtD
Theophylline—Anorexia—Gemcitabine—urinary bladder cancer	0.000373	0.00213	CcSEcCtD
Theophylline—Urticaria—Thiotepa—urinary bladder cancer	0.000369	0.00211	CcSEcCtD
Theophylline—Body temperature increased—Thiotepa—urinary bladder cancer	0.000367	0.0021	CcSEcCtD
Theophylline—Abdominal pain—Thiotepa—urinary bladder cancer	0.000367	0.0021	CcSEcCtD
Theophylline—Anorexia—Fluorouracil—urinary bladder cancer	0.000366	0.00209	CcSEcCtD
Theophylline—Hypotension—Gemcitabine—urinary bladder cancer	0.000365	0.00209	CcSEcCtD
Theophylline—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.000364	0.00208	CcSEcCtD
Theophylline—Anaphylactoid reaction—Doxorubicin—urinary bladder cancer	0.000364	0.00208	CcSEcCtD
Theophylline—Infection—Cisplatin—urinary bladder cancer	0.000362	0.00207	CcSEcCtD
Theophylline—Hypotension—Fluorouracil—urinary bladder cancer	0.000359	0.00205	CcSEcCtD
Theophylline—Nervous system disorder—Cisplatin—urinary bladder cancer	0.000357	0.00204	CcSEcCtD
Theophylline—Tachycardia—Cisplatin—urinary bladder cancer	0.000356	0.00203	CcSEcCtD
Theophylline—CYP1A1—lymph node—urinary bladder cancer	0.000355	0.00206	CbGeAlD
Theophylline—Convulsion—Etoposide—urinary bladder cancer	0.000354	0.00202	CcSEcCtD
Theophylline—Insomnia—Gemcitabine—urinary bladder cancer	0.000354	0.00202	CcSEcCtD
Theophylline—Abdominal pain upper—Epirubicin—urinary bladder cancer	0.000348	0.00198	CcSEcCtD
Theophylline—Insomnia—Fluorouracil—urinary bladder cancer	0.000348	0.00198	CcSEcCtD
Theophylline—Anorexia—Cisplatin—urinary bladder cancer	0.000347	0.00198	CcSEcCtD
Theophylline—Hypokalaemia—Epirubicin—urinary bladder cancer	0.000346	0.00198	CcSEcCtD
Theophylline—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000342	0.00195	CcSEcCtD
Theophylline—Hypotension—Cisplatin—urinary bladder cancer	0.00034	0.00194	CcSEcCtD
Theophylline—Decreased appetite—Gemcitabine—urinary bladder cancer	0.00034	0.00194	CcSEcCtD
Theophylline—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000334	0.00191	CcSEcCtD
Theophylline—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000334	0.00191	CcSEcCtD
Theophylline—Infection—Etoposide—urinary bladder cancer	0.000332	0.00189	CcSEcCtD
Theophylline—Pruritus—Thiotepa—urinary bladder cancer	0.000329	0.00188	CcSEcCtD
Theophylline—Tachycardia—Etoposide—urinary bladder cancer	0.000326	0.00186	CcSEcCtD
Theophylline—Abdominal pain upper—Doxorubicin—urinary bladder cancer	0.000322	0.00184	CcSEcCtD
Theophylline—Hypokalaemia—Doxorubicin—urinary bladder cancer	0.000321	0.00183	CcSEcCtD
Theophylline—Anorexia—Etoposide—urinary bladder cancer	0.000318	0.00182	CcSEcCtD
Theophylline—Diarrhoea—Thiotepa—urinary bladder cancer	0.000318	0.00181	CcSEcCtD
Theophylline—Decreased appetite—Cisplatin—urinary bladder cancer	0.000317	0.00181	CcSEcCtD
Theophylline—Hypotension—Etoposide—urinary bladder cancer	0.000312	0.00178	CcSEcCtD
Theophylline—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000309	0.00176	CcSEcCtD
Theophylline—Dizziness—Thiotepa—urinary bladder cancer	0.000307	0.00175	CcSEcCtD
Theophylline—Urticaria—Fluorouracil—urinary bladder cancer	0.000305	0.00174	CcSEcCtD
Theophylline—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000304	0.00173	CcSEcCtD
Theophylline—Haematuria—Methotrexate—urinary bladder cancer	0.000299	0.00171	CcSEcCtD
Theophylline—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.000297	0.00169	CcSEcCtD
Theophylline—Vomiting—Thiotepa—urinary bladder cancer	0.000295	0.00169	CcSEcCtD
Theophylline—Rash—Thiotepa—urinary bladder cancer	0.000293	0.00167	CcSEcCtD
Theophylline—Dermatitis—Thiotepa—urinary bladder cancer	0.000293	0.00167	CcSEcCtD
Theophylline—Headache—Thiotepa—urinary bladder cancer	0.000291	0.00166	CcSEcCtD
Theophylline—Decreased appetite—Etoposide—urinary bladder cancer	0.00029	0.00166	CcSEcCtD
Theophylline—Body temperature increased—Cisplatin—urinary bladder cancer	0.000288	0.00164	CcSEcCtD
Theophylline—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000283	0.00162	CcSEcCtD
Theophylline—Haematuria—Epirubicin—urinary bladder cancer	0.00028	0.0016	CcSEcCtD
Theophylline—Pruritus—Gemcitabine—urinary bladder cancer	0.000277	0.00158	CcSEcCtD
Theophylline—Nausea—Thiotepa—urinary bladder cancer	0.000276	0.00158	CcSEcCtD
Theophylline—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000275	0.00157	CcSEcCtD
Theophylline—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000273	0.00156	CcSEcCtD
Theophylline—Pruritus—Fluorouracil—urinary bladder cancer	0.000272	0.00155	CcSEcCtD
Theophylline—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000268	0.00153	CcSEcCtD
Theophylline—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000267	0.00153	CcSEcCtD
Theophylline—Urticaria—Etoposide—urinary bladder cancer	0.000265	0.00151	CcSEcCtD
Theophylline—Abdominal pain—Etoposide—urinary bladder cancer	0.000264	0.00151	CcSEcCtD
Theophylline—Body temperature increased—Etoposide—urinary bladder cancer	0.000264	0.00151	CcSEcCtD
Theophylline—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000263	0.0015	CcSEcCtD
Theophylline—Haematuria—Doxorubicin—urinary bladder cancer	0.000259	0.00148	CcSEcCtD
Theophylline—Dizziness—Fluorouracil—urinary bladder cancer	0.000254	0.00145	CcSEcCtD
Theophylline—Diarrhoea—Cisplatin—urinary bladder cancer	0.000249	0.00142	CcSEcCtD
Theophylline—Alopecia—Methotrexate—urinary bladder cancer	0.000249	0.00142	CcSEcCtD
Theophylline—Vomiting—Gemcitabine—urinary bladder cancer	0.000249	0.00142	CcSEcCtD
Theophylline—Rash—Gemcitabine—urinary bladder cancer	0.000246	0.00141	CcSEcCtD
Theophylline—Dermatitis—Gemcitabine—urinary bladder cancer	0.000246	0.00141	CcSEcCtD
Theophylline—Hypersensitivity—Etoposide—urinary bladder cancer	0.000246	0.0014	CcSEcCtD
Theophylline—Headache—Gemcitabine—urinary bladder cancer	0.000245	0.0014	CcSEcCtD
Theophylline—Flushing—Epirubicin—urinary bladder cancer	0.000244	0.0014	CcSEcCtD
Theophylline—Vomiting—Fluorouracil—urinary bladder cancer	0.000244	0.00139	CcSEcCtD
Theophylline—Rash—Fluorouracil—urinary bladder cancer	0.000242	0.00138	CcSEcCtD
Theophylline—Dermatitis—Fluorouracil—urinary bladder cancer	0.000242	0.00138	CcSEcCtD
Theophylline—Headache—Fluorouracil—urinary bladder cancer	0.000241	0.00137	CcSEcCtD
Theophylline—Pruritus—Etoposide—urinary bladder cancer	0.000236	0.00135	CcSEcCtD
Theophylline—Arrhythmia—Epirubicin—urinary bladder cancer	0.000235	0.00134	CcSEcCtD
Theophylline—Alopecia—Epirubicin—urinary bladder cancer	0.000233	0.00133	CcSEcCtD
Theophylline—Nausea—Gemcitabine—urinary bladder cancer	0.000232	0.00133	CcSEcCtD
Theophylline—Vomiting—Cisplatin—urinary bladder cancer	0.000232	0.00132	CcSEcCtD
Theophylline—Rash—Cisplatin—urinary bladder cancer	0.00023	0.00131	CcSEcCtD
Theophylline—Dermatitis—Cisplatin—urinary bladder cancer	0.00023	0.00131	CcSEcCtD
Theophylline—Diarrhoea—Etoposide—urinary bladder cancer	0.000228	0.0013	CcSEcCtD
Theophylline—Nausea—Fluorouracil—urinary bladder cancer	0.000228	0.0013	CcSEcCtD
Theophylline—Flushing—Doxorubicin—urinary bladder cancer	0.000226	0.00129	CcSEcCtD
Theophylline—Tension—Epirubicin—urinary bladder cancer	0.000225	0.00128	CcSEcCtD
Theophylline—Nervousness—Epirubicin—urinary bladder cancer	0.000223	0.00127	CcSEcCtD
Theophylline—Dizziness—Etoposide—urinary bladder cancer	0.000221	0.00126	CcSEcCtD
Theophylline—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000218	0.00124	CcSEcCtD
Theophylline—Nausea—Cisplatin—urinary bladder cancer	0.000216	0.00124	CcSEcCtD
Theophylline—Alopecia—Doxorubicin—urinary bladder cancer	0.000215	0.00123	CcSEcCtD
Theophylline—Convulsion—Methotrexate—urinary bladder cancer	0.000212	0.00121	CcSEcCtD
Theophylline—Vomiting—Etoposide—urinary bladder cancer	0.000212	0.00121	CcSEcCtD
Theophylline—Agitation—Epirubicin—urinary bladder cancer	0.000211	0.0012	CcSEcCtD
Theophylline—Rash—Etoposide—urinary bladder cancer	0.00021	0.0012	CcSEcCtD
Theophylline—Dermatitis—Etoposide—urinary bladder cancer	0.00021	0.0012	CcSEcCtD
Theophylline—Headache—Etoposide—urinary bladder cancer	0.000209	0.00119	CcSEcCtD
Theophylline—Tension—Doxorubicin—urinary bladder cancer	0.000208	0.00119	CcSEcCtD
Theophylline—Nervousness—Doxorubicin—urinary bladder cancer	0.000206	0.00118	CcSEcCtD
Theophylline—Palpitations—Epirubicin—urinary bladder cancer	0.000203	0.00116	CcSEcCtD
Theophylline—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.0002	0.00114	CcSEcCtD
Theophylline—Convulsion—Epirubicin—urinary bladder cancer	0.000199	0.00113	CcSEcCtD
Theophylline—Infection—Methotrexate—urinary bladder cancer	0.000199	0.00113	CcSEcCtD
Theophylline—Nausea—Etoposide—urinary bladder cancer	0.000198	0.00113	CcSEcCtD
Theophylline—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000196	0.00112	CcSEcCtD
Theophylline—Agitation—Doxorubicin—urinary bladder cancer	0.000195	0.00111	CcSEcCtD
Theophylline—Anxiety—Epirubicin—urinary bladder cancer	0.000195	0.00111	CcSEcCtD
Theophylline—Anorexia—Methotrexate—urinary bladder cancer	0.000191	0.00109	CcSEcCtD
Theophylline—Palpitations—Doxorubicin—urinary bladder cancer	0.000187	0.00107	CcSEcCtD
Theophylline—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000187	0.00107	CcSEcCtD
Theophylline—Hypotension—Methotrexate—urinary bladder cancer	0.000187	0.00107	CcSEcCtD
Theophylline—Infection—Epirubicin—urinary bladder cancer	0.000186	0.00106	CcSEcCtD
Theophylline—Shock—Epirubicin—urinary bladder cancer	0.000184	0.00105	CcSEcCtD
Theophylline—Convulsion—Doxorubicin—urinary bladder cancer	0.000184	0.00105	CcSEcCtD
Theophylline—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000183	0.00105	CcSEcCtD
Theophylline—Tachycardia—Epirubicin—urinary bladder cancer	0.000183	0.00104	CcSEcCtD
Theophylline—Insomnia—Methotrexate—urinary bladder cancer	0.000181	0.00103	CcSEcCtD
Theophylline—Anxiety—Doxorubicin—urinary bladder cancer	0.00018	0.00103	CcSEcCtD
Theophylline—Anorexia—Epirubicin—urinary bladder cancer	0.000178	0.00102	CcSEcCtD
Theophylline—Hypotension—Epirubicin—urinary bladder cancer	0.000175	0.000998	CcSEcCtD
Theophylline—Decreased appetite—Methotrexate—urinary bladder cancer	0.000174	0.000992	CcSEcCtD
Theophylline—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000173	0.000988	CcSEcCtD
Theophylline—Infection—Doxorubicin—urinary bladder cancer	0.000172	0.000982	CcSEcCtD
Theophylline—Shock—Doxorubicin—urinary bladder cancer	0.00017	0.000972	CcSEcCtD
Theophylline—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.00017	0.000969	CcSEcCtD
Theophylline—Insomnia—Epirubicin—urinary bladder cancer	0.000169	0.000966	CcSEcCtD
Theophylline—Tachycardia—Doxorubicin—urinary bladder cancer	0.000169	0.000965	CcSEcCtD
Theophylline—Anorexia—Doxorubicin—urinary bladder cancer	0.000165	0.000942	CcSEcCtD
Theophylline—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000163	0.000933	CcSEcCtD
Theophylline—Decreased appetite—Epirubicin—urinary bladder cancer	0.000163	0.000928	CcSEcCtD
Theophylline—Hypotension—Doxorubicin—urinary bladder cancer	0.000162	0.000923	CcSEcCtD
Theophylline—Urticaria—Methotrexate—urinary bladder cancer	0.000159	0.000907	CcSEcCtD
Theophylline—Body temperature increased—Methotrexate—urinary bladder cancer	0.000158	0.000902	CcSEcCtD
Theophylline—Abdominal pain—Methotrexate—urinary bladder cancer	0.000158	0.000902	CcSEcCtD
Theophylline—Insomnia—Doxorubicin—urinary bladder cancer	0.000157	0.000894	CcSEcCtD
Theophylline—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000153	0.000873	CcSEcCtD
Theophylline—Decreased appetite—Doxorubicin—urinary bladder cancer	0.00015	0.000859	CcSEcCtD
Theophylline—Urticaria—Epirubicin—urinary bladder cancer	0.000149	0.000849	CcSEcCtD
Theophylline—Abdominal pain—Epirubicin—urinary bladder cancer	0.000148	0.000844	CcSEcCtD
Theophylline—Body temperature increased—Epirubicin—urinary bladder cancer	0.000148	0.000844	CcSEcCtD
Theophylline—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000147	0.000841	CcSEcCtD
Theophylline—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000142	0.000808	CcSEcCtD
Theophylline—Pruritus—Methotrexate—urinary bladder cancer	0.000141	0.000807	CcSEcCtD
Theophylline—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000138	0.000787	CcSEcCtD
Theophylline—Urticaria—Doxorubicin—urinary bladder cancer	0.000138	0.000785	CcSEcCtD
Theophylline—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000137	0.000781	CcSEcCtD
Theophylline—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000137	0.000781	CcSEcCtD
Theophylline—Diarrhoea—Methotrexate—urinary bladder cancer	0.000137	0.000781	CcSEcCtD
Theophylline—Pruritus—Epirubicin—urinary bladder cancer	0.000132	0.000756	CcSEcCtD
Theophylline—Dizziness—Methotrexate—urinary bladder cancer	0.000132	0.000755	CcSEcCtD
Theophylline—Diarrhoea—Epirubicin—urinary bladder cancer	0.000128	0.000731	CcSEcCtD
Theophylline—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000128	0.000728	CcSEcCtD
Theophylline—Vomiting—Methotrexate—urinary bladder cancer	0.000127	0.000726	CcSEcCtD
Theophylline—Rash—Methotrexate—urinary bladder cancer	0.000126	0.00072	CcSEcCtD
Theophylline—Dermatitis—Methotrexate—urinary bladder cancer	0.000126	0.000719	CcSEcCtD
Theophylline—Headache—Methotrexate—urinary bladder cancer	0.000125	0.000715	CcSEcCtD
Theophylline—Dizziness—Epirubicin—urinary bladder cancer	0.000124	0.000706	CcSEcCtD
Theophylline—Pruritus—Doxorubicin—urinary bladder cancer	0.000122	0.000699	CcSEcCtD
Theophylline—Vomiting—Epirubicin—urinary bladder cancer	0.000119	0.000679	CcSEcCtD
Theophylline—Nausea—Methotrexate—urinary bladder cancer	0.000119	0.000678	CcSEcCtD
Theophylline—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000118	0.000676	CcSEcCtD
Theophylline—Rash—Epirubicin—urinary bladder cancer	0.000118	0.000673	CcSEcCtD
Theophylline—Dermatitis—Epirubicin—urinary bladder cancer	0.000118	0.000673	CcSEcCtD
Theophylline—Headache—Epirubicin—urinary bladder cancer	0.000117	0.000669	CcSEcCtD
Theophylline—Dizziness—Doxorubicin—urinary bladder cancer	0.000114	0.000654	CcSEcCtD
Theophylline—Nausea—Epirubicin—urinary bladder cancer	0.000111	0.000634	CcSEcCtD
Theophylline—Vomiting—Doxorubicin—urinary bladder cancer	0.00011	0.000628	CcSEcCtD
Theophylline—Rash—Doxorubicin—urinary bladder cancer	0.000109	0.000623	CcSEcCtD
Theophylline—Dermatitis—Doxorubicin—urinary bladder cancer	0.000109	0.000623	CcSEcCtD
Theophylline—Headache—Doxorubicin—urinary bladder cancer	0.000108	0.000619	CcSEcCtD
Theophylline—Nausea—Doxorubicin—urinary bladder cancer	0.000103	0.000587	CcSEcCtD
Theophylline—PDE4D—Signaling Pathways—PTEN—urinary bladder cancer	1.54e-05	7.48e-05	CbGpPWpGaD
Theophylline—ADORA2B—Signaling Pathways—EP300—urinary bladder cancer	1.54e-05	7.48e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.54e-05	7.47e-05	CbGpPWpGaD
Theophylline—ADORA1—Signaling Pathways—CXCL8—urinary bladder cancer	1.52e-05	7.41e-05	CbGpPWpGaD
Theophylline—PDE4A—Signaling Pathways—CCND1—urinary bladder cancer	1.52e-05	7.38e-05	CbGpPWpGaD
Theophylline—ADORA1—Signaling by GPCR—HRAS—urinary bladder cancer	1.51e-05	7.37e-05	CbGpPWpGaD
Theophylline—PDE3A—Signaling Pathways—IL2—urinary bladder cancer	1.51e-05	7.36e-05	CbGpPWpGaD
Theophylline—HDAC2—Disease—SRC—urinary bladder cancer	1.51e-05	7.33e-05	CbGpPWpGaD
Theophylline—PDE4B—Signaling Pathways—CXCL8—urinary bladder cancer	1.51e-05	7.33e-05	CbGpPWpGaD
Theophylline—PDE4B—Signaling by GPCR—HRAS—urinary bladder cancer	1.5e-05	7.28e-05	CbGpPWpGaD
Theophylline—ADORA2B—Signaling Pathways—SRC—urinary bladder cancer	1.49e-05	7.27e-05	CbGpPWpGaD
Theophylline—PDE3B—Signaling Pathways—EP300—urinary bladder cancer	1.49e-05	7.25e-05	CbGpPWpGaD
Theophylline—ADORA2A—Signaling Pathways—CREBBP—urinary bladder cancer	1.48e-05	7.21e-05	CbGpPWpGaD
Theophylline—PDE3A—Signaling Pathways—CCND1—urinary bladder cancer	1.47e-05	7.18e-05	CbGpPWpGaD
Theophylline—CYP2D6—Metabolism—RRM2—urinary bladder cancer	1.47e-05	7.17e-05	CbGpPWpGaD
Theophylline—PDE4A—Signaling Pathways—MMP9—urinary bladder cancer	1.47e-05	7.16e-05	CbGpPWpGaD
Theophylline—PDE4C—Signaling Pathways—MYC—urinary bladder cancer	1.47e-05	7.14e-05	CbGpPWpGaD
Theophylline—PDE4A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.47e-05	7.14e-05	CbGpPWpGaD
Theophylline—PDE4D—Signaling Pathways—EP300—urinary bladder cancer	1.47e-05	7.13e-05	CbGpPWpGaD
Theophylline—PDE4A—Signaling Pathways—PTEN—urinary bladder cancer	1.46e-05	7.12e-05	CbGpPWpGaD
Theophylline—ADORA2A—Signaling Pathways—IGF1—urinary bladder cancer	1.46e-05	7.12e-05	CbGpPWpGaD
Theophylline—CYP1A1—Metabolism—NQO1—urinary bladder cancer	1.46e-05	7.11e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism—RRM2—urinary bladder cancer	1.46e-05	7.11e-05	CbGpPWpGaD
Theophylline—ADORA1—Signaling Pathways—IL2—urinary bladder cancer	1.46e-05	7.09e-05	CbGpPWpGaD
Theophylline—ADORA2A—Signaling by GPCR—EGFR—urinary bladder cancer	1.46e-05	7.08e-05	CbGpPWpGaD
Theophylline—HDAC2—Gene Expression—MYC—urinary bladder cancer	1.45e-05	7.08e-05	CbGpPWpGaD
Theophylline—PDE3B—Signaling Pathways—SRC—urinary bladder cancer	1.45e-05	7.05e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism—NAT2—urinary bladder cancer	1.45e-05	7.04e-05	CbGpPWpGaD
Theophylline—HDAC2—Signaling Pathways—RHOA—urinary bladder cancer	1.44e-05	7.01e-05	CbGpPWpGaD
Theophylline—PDE4B—Signaling Pathways—IL2—urinary bladder cancer	1.44e-05	7e-05	CbGpPWpGaD
Theophylline—PDE4C—Signaling Pathways—EGFR—urinary bladder cancer	1.44e-05	6.98e-05	CbGpPWpGaD
Theophylline—PDE3A—Signaling Pathways—MMP9—urinary bladder cancer	1.43e-05	6.97e-05	CbGpPWpGaD
Theophylline—PDE3A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.43e-05	6.94e-05	CbGpPWpGaD
Theophylline—PDE4D—Signaling Pathways—SRC—urinary bladder cancer	1.43e-05	6.94e-05	CbGpPWpGaD
Theophylline—PDE3A—Signaling Pathways—PTEN—urinary bladder cancer	1.42e-05	6.93e-05	CbGpPWpGaD
Theophylline—ADORA1—Signaling Pathways—CCND1—urinary bladder cancer	1.42e-05	6.91e-05	CbGpPWpGaD
Theophylline—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.42e-05	6.9e-05	CbGpPWpGaD
Theophylline—PDE4B—Signaling Pathways—CCND1—urinary bladder cancer	1.4e-05	6.83e-05	CbGpPWpGaD
Theophylline—PDE4A—Signaling Pathways—EP300—urinary bladder cancer	1.4e-05	6.79e-05	CbGpPWpGaD
Theophylline—ADORA1—Signaling Pathways—MMP9—urinary bladder cancer	1.38e-05	6.71e-05	CbGpPWpGaD
Theophylline—ADORA2A—Signaling by GPCR—KRAS—urinary bladder cancer	1.38e-05	6.69e-05	CbGpPWpGaD
Theophylline—ADORA1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.37e-05	6.68e-05	CbGpPWpGaD
Theophylline—ADORA1—Signaling Pathways—PTEN—urinary bladder cancer	1.37e-05	6.67e-05	CbGpPWpGaD
Theophylline—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	1.36e-05	6.64e-05	CbGpPWpGaD
Theophylline—CYP2D6—Metabolism—ENO2—urinary bladder cancer	1.36e-05	6.64e-05	CbGpPWpGaD
Theophylline—PDE4B—Signaling Pathways—MMP9—urinary bladder cancer	1.36e-05	6.63e-05	CbGpPWpGaD
Theophylline—PDE3A—Signaling Pathways—EP300—urinary bladder cancer	1.36e-05	6.61e-05	CbGpPWpGaD
Theophylline—PDE4B—Signaling Pathways—CDKN1A—urinary bladder cancer	1.36e-05	6.6e-05	CbGpPWpGaD
Theophylline—PDE4A—Signaling Pathways—SRC—urinary bladder cancer	1.36e-05	6.6e-05	CbGpPWpGaD
Theophylline—PDE4C—Signaling Pathways—KRAS—urinary bladder cancer	1.36e-05	6.6e-05	CbGpPWpGaD
Theophylline—PDE4B—Signaling Pathways—PTEN—urinary bladder cancer	1.35e-05	6.59e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	1.35e-05	6.58e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism—ENO2—urinary bladder cancer	1.35e-05	6.58e-05	CbGpPWpGaD
Theophylline—HDAC2—Disease—MYC—urinary bladder cancer	1.35e-05	6.57e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.34e-05	6.54e-05	CbGpPWpGaD
Theophylline—ADORA2A—Signaling Pathways—RHOA—urinary bladder cancer	1.34e-05	6.52e-05	CbGpPWpGaD
Theophylline—CYP2C8—Metabolism—NQO1—urinary bladder cancer	1.34e-05	6.52e-05	CbGpPWpGaD
Theophylline—ADORA2B—Signaling Pathways—MYC—urinary bladder cancer	1.34e-05	6.52e-05	CbGpPWpGaD
Theophylline—HDAC2—Signaling Pathways—ERBB2—urinary bladder cancer	1.33e-05	6.49e-05	CbGpPWpGaD
Theophylline—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	1.32e-05	6.44e-05	CbGpPWpGaD
Theophylline—HDAC2—Disease—EGFR—urinary bladder cancer	1.32e-05	6.43e-05	CbGpPWpGaD
Theophylline—PDE3A—Signaling Pathways—SRC—urinary bladder cancer	1.32e-05	6.42e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	1.31e-05	6.38e-05	CbGpPWpGaD
Theophylline—ADORA2B—Signaling Pathways—EGFR—urinary bladder cancer	1.31e-05	6.37e-05	CbGpPWpGaD
Theophylline—ADORA1—Signaling Pathways—EP300—urinary bladder cancer	1.31e-05	6.36e-05	CbGpPWpGaD
Theophylline—CYP1B1—Metabolism—PPARG—urinary bladder cancer	1.3e-05	6.34e-05	CbGpPWpGaD
Theophylline—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.3e-05	6.33e-05	CbGpPWpGaD
Theophylline—PDE3B—Signaling Pathways—MYC—urinary bladder cancer	1.3e-05	6.32e-05	CbGpPWpGaD
Theophylline—CYP2E1—Metabolism—GSTP1—urinary bladder cancer	1.29e-05	6.29e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.29e-05	6.29e-05	CbGpPWpGaD
Theophylline—PDE4B—Signaling Pathways—EP300—urinary bladder cancer	1.29e-05	6.28e-05	CbGpPWpGaD
Theophylline—PDE4D—Signaling Pathways—MYC—urinary bladder cancer	1.28e-05	6.22e-05	CbGpPWpGaD
Theophylline—ADORA1—Signaling Pathways—SRC—urinary bladder cancer	1.27e-05	6.18e-05	CbGpPWpGaD
Theophylline—PDE3B—Signaling Pathways—EGFR—urinary bladder cancer	1.27e-05	6.18e-05	CbGpPWpGaD
Theophylline—HDAC2—Signaling Pathways—CXCL8—urinary bladder cancer	1.27e-05	6.16e-05	CbGpPWpGaD
Theophylline—PDE4B—Signaling Pathways—SRC—urinary bladder cancer	1.26e-05	6.11e-05	CbGpPWpGaD
Theophylline—CYP1B1—Metabolism—CREBBP—urinary bladder cancer	1.25e-05	6.09e-05	CbGpPWpGaD
Theophylline—PDE4D—Signaling Pathways—EGFR—urinary bladder cancer	1.25e-05	6.08e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism—RRM2—urinary bladder cancer	1.25e-05	6.07e-05	CbGpPWpGaD
Theophylline—HDAC2—Disease—KRAS—urinary bladder cancer	1.25e-05	6.07e-05	CbGpPWpGaD
Theophylline—ADORA2A—Signaling Pathways—ERBB2—urinary bladder cancer	1.24e-05	6.04e-05	CbGpPWpGaD
Theophylline—ADORA2B—Signaling Pathways—KRAS—urinary bladder cancer	1.24e-05	6.02e-05	CbGpPWpGaD
Theophylline—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.24e-05	6.02e-05	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.23e-05	6e-05	CbGpPWpGaD
Theophylline—CYP1A1—Metabolism—GSTP1—urinary bladder cancer	1.22e-05	5.93e-05	CbGpPWpGaD
Theophylline—PDE4A—Signaling Pathways—MYC—urinary bladder cancer	1.22e-05	5.92e-05	CbGpPWpGaD
Theophylline—HDAC2—Signaling Pathways—IL2—urinary bladder cancer	1.21e-05	5.88e-05	CbGpPWpGaD
Theophylline—PDE4C—Signaling Pathways—TP53—urinary bladder cancer	1.21e-05	5.86e-05	CbGpPWpGaD
Theophylline—CYP2E1—Metabolism—TYMS—urinary bladder cancer	1.2e-05	5.85e-05	CbGpPWpGaD
Theophylline—PDE3B—Signaling Pathways—KRAS—urinary bladder cancer	1.2e-05	5.84e-05	CbGpPWpGaD
Theophylline—PDE4A—Signaling Pathways—EGFR—urinary bladder cancer	1.19e-05	5.79e-05	CbGpPWpGaD
Theophylline—CYP2E1—Metabolism—NCOR1—urinary bladder cancer	1.19e-05	5.78e-05	CbGpPWpGaD
Theophylline—CYP2E1—Metabolism—GSTM1—urinary bladder cancer	1.19e-05	5.78e-05	CbGpPWpGaD
Theophylline—PDE3A—Signaling Pathways—MYC—urinary bladder cancer	1.18e-05	5.76e-05	CbGpPWpGaD
Theophylline—PDE4D—Signaling Pathways—KRAS—urinary bladder cancer	1.18e-05	5.74e-05	CbGpPWpGaD
Theophylline—CYP1A1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.18e-05	5.74e-05	CbGpPWpGaD
Theophylline—HDAC2—Signaling Pathways—CCND1—urinary bladder cancer	1.18e-05	5.74e-05	CbGpPWpGaD
Theophylline—ADORA2A—Signaling Pathways—CXCL8—urinary bladder cancer	1.18e-05	5.72e-05	CbGpPWpGaD
Theophylline—ADORA2A—Signaling by GPCR—HRAS—urinary bladder cancer	1.17e-05	5.69e-05	CbGpPWpGaD
Theophylline—PDE3A—Signaling Pathways—EGFR—urinary bladder cancer	1.16e-05	5.63e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	1.16e-05	5.62e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism—ENO2—urinary bladder cancer	1.16e-05	5.62e-05	CbGpPWpGaD
Theophylline—PDE4C—Signaling Pathways—HRAS—urinary bladder cancer	1.15e-05	5.61e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.15e-05	5.59e-05	CbGpPWpGaD
Theophylline—HDAC2—Signaling Pathways—MMP9—urinary bladder cancer	1.14e-05	5.57e-05	CbGpPWpGaD
Theophylline—HDAC2—Signaling Pathways—CDKN1A—urinary bladder cancer	1.14e-05	5.55e-05	CbGpPWpGaD
Theophylline—ADORA1—Signaling Pathways—MYC—urinary bladder cancer	1.14e-05	5.54e-05	CbGpPWpGaD
Theophylline—HDAC2—Signaling Pathways—PTEN—urinary bladder cancer	1.14e-05	5.54e-05	CbGpPWpGaD
Theophylline—CYP2E1—Metabolism—GPX1—urinary bladder cancer	1.14e-05	5.54e-05	CbGpPWpGaD
Theophylline—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.13e-05	5.52e-05	CbGpPWpGaD
Theophylline—CYP1A1—Metabolism—TYMS—urinary bladder cancer	1.13e-05	5.51e-05	CbGpPWpGaD
Theophylline—PDE4B—Signaling Pathways—MYC—urinary bladder cancer	1.13e-05	5.47e-05	CbGpPWpGaD
Theophylline—ADORA2A—Signaling Pathways—IL2—urinary bladder cancer	1.12e-05	5.47e-05	CbGpPWpGaD
Theophylline—PDE4A—Signaling Pathways—KRAS—urinary bladder cancer	1.12e-05	5.47e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	1.12e-05	5.46e-05	CbGpPWpGaD
Theophylline—CYP1A1—Metabolism—GSTM1—urinary bladder cancer	1.12e-05	5.45e-05	CbGpPWpGaD
Theophylline—CYP1A1—Metabolism—NCOR1—urinary bladder cancer	1.12e-05	5.45e-05	CbGpPWpGaD
Theophylline—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	1.12e-05	5.44e-05	CbGpPWpGaD
Theophylline—CYP2E1—Metabolism—ERCC2—urinary bladder cancer	1.12e-05	5.44e-05	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.12e-05	5.43e-05	CbGpPWpGaD
Theophylline—ADORA1—Signaling Pathways—EGFR—urinary bladder cancer	1.11e-05	5.42e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.1e-05	5.37e-05	CbGpPWpGaD
Theophylline—PDE4B—Signaling Pathways—EGFR—urinary bladder cancer	1.1e-05	5.35e-05	CbGpPWpGaD
Theophylline—CYP2D6—Metabolism—NQO1—urinary bladder cancer	1.1e-05	5.35e-05	CbGpPWpGaD
Theophylline—ADORA2B—Signaling Pathways—TP53—urinary bladder cancer	1.1e-05	5.35e-05	CbGpPWpGaD
Theophylline—ADORA2A—Signaling Pathways—CCND1—urinary bladder cancer	1.1e-05	5.33e-05	CbGpPWpGaD
Theophylline—PDE3A—Signaling Pathways—KRAS—urinary bladder cancer	1.09e-05	5.32e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism—NQO1—urinary bladder cancer	1.09e-05	5.31e-05	CbGpPWpGaD
Theophylline—HDAC2—Signaling Pathways—EP300—urinary bladder cancer	1.09e-05	5.28e-05	CbGpPWpGaD
Theophylline—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.08e-05	5.26e-05	CbGpPWpGaD
Theophylline—CYP1A1—Metabolism—GPX1—urinary bladder cancer	1.07e-05	5.22e-05	CbGpPWpGaD
Theophylline—PDE3B—Signaling Pathways—TP53—urinary bladder cancer	1.07e-05	5.19e-05	CbGpPWpGaD
Theophylline—ADORA2A—Signaling Pathways—MMP9—urinary bladder cancer	1.06e-05	5.18e-05	CbGpPWpGaD
Theophylline—HDAC2—Disease—HRAS—urinary bladder cancer	1.06e-05	5.16e-05	CbGpPWpGaD
Theophylline—ADORA2A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.06e-05	5.16e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.06e-05	5.15e-05	CbGpPWpGaD
Theophylline—ADORA2A—Signaling Pathways—PTEN—urinary bladder cancer	1.06e-05	5.15e-05	CbGpPWpGaD
Theophylline—HDAC2—Signaling Pathways—SRC—urinary bladder cancer	1.06e-05	5.13e-05	CbGpPWpGaD
Theophylline—CYP1A1—Metabolism—ERCC2—urinary bladder cancer	1.05e-05	5.12e-05	CbGpPWpGaD
Theophylline—ADORA1—Signaling Pathways—KRAS—urinary bladder cancer	1.05e-05	5.12e-05	CbGpPWpGaD
Theophylline—ADORA2B—Signaling Pathways—HRAS—urinary bladder cancer	1.05e-05	5.12e-05	CbGpPWpGaD
Theophylline—CYP2E1—Metabolism—MTHFR—urinary bladder cancer	1.05e-05	5.11e-05	CbGpPWpGaD
Theophylline—PDE4D—Signaling Pathways—TP53—urinary bladder cancer	1.05e-05	5.1e-05	CbGpPWpGaD
Theophylline—PDE4B—Signaling Pathways—KRAS—urinary bladder cancer	1.04e-05	5.06e-05	CbGpPWpGaD
Theophylline—CYP2C8—Metabolism—TYMS—urinary bladder cancer	1.04e-05	5.05e-05	CbGpPWpGaD
Theophylline—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	1.03e-05	5e-05	CbGpPWpGaD
Theophylline—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	1.03e-05	5e-05	CbGpPWpGaD
Theophylline—CYP1B1—Metabolism—PTGS2—urinary bladder cancer	1.03e-05	4.99e-05	CbGpPWpGaD
Theophylline—PDE3B—Signaling Pathways—HRAS—urinary bladder cancer	1.02e-05	4.96e-05	CbGpPWpGaD
Theophylline—ADORA2A—Signaling Pathways—EP300—urinary bladder cancer	1.01e-05	4.91e-05	CbGpPWpGaD
Theophylline—PDE4D—Signaling Pathways—HRAS—urinary bladder cancer	1e-05	4.88e-05	CbGpPWpGaD
Theophylline—PDE4A—Signaling Pathways—TP53—urinary bladder cancer	9.99e-06	4.86e-05	CbGpPWpGaD
Theophylline—CYP1A1—Metabolism—MTHFR—urinary bladder cancer	9.9e-06	4.82e-05	CbGpPWpGaD
Theophylline—CYP2C8—Metabolism—GPX1—urinary bladder cancer	9.83e-06	4.78e-05	CbGpPWpGaD
Theophylline—ADORA2A—Signaling Pathways—SRC—urinary bladder cancer	9.81e-06	4.77e-05	CbGpPWpGaD
Theophylline—PDE3A—Signaling Pathways—TP53—urinary bladder cancer	9.71e-06	4.73e-05	CbGpPWpGaD
Theophylline—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	9.65e-06	4.7e-05	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—RRM2—urinary bladder cancer	9.63e-06	4.69e-05	CbGpPWpGaD
Theophylline—PDE4A—Signaling Pathways—HRAS—urinary bladder cancer	9.55e-06	4.65e-05	CbGpPWpGaD
Theophylline—HDAC2—Signaling Pathways—MYC—urinary bladder cancer	9.46e-06	4.6e-05	CbGpPWpGaD
Theophylline—ADORA1—Signaling Pathways—TP53—urinary bladder cancer	9.35e-06	4.55e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism—NQO1—urinary bladder cancer	9.32e-06	4.53e-05	CbGpPWpGaD
Theophylline—PDE3A—Signaling Pathways—HRAS—urinary bladder cancer	9.29e-06	4.52e-05	CbGpPWpGaD
Theophylline—HDAC2—Signaling Pathways—EGFR—urinary bladder cancer	9.25e-06	4.5e-05	CbGpPWpGaD
Theophylline—PDE4B—Signaling Pathways—TP53—urinary bladder cancer	9.24e-06	4.5e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	9.23e-06	4.49e-05	CbGpPWpGaD
Theophylline—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	9.17e-06	4.46e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	9.09e-06	4.43e-05	CbGpPWpGaD
Theophylline—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	9.07e-06	4.42e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	9.04e-06	4.4e-05	CbGpPWpGaD
Theophylline—ADORA1—Signaling Pathways—HRAS—urinary bladder cancer	8.94e-06	4.35e-05	CbGpPWpGaD
Theophylline—CYP1B1—Metabolism—PTEN—urinary bladder cancer	8.94e-06	4.35e-05	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—ENO2—urinary bladder cancer	8.92e-06	4.34e-05	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	8.92e-06	4.34e-05	CbGpPWpGaD
Theophylline—PDE4B—Signaling Pathways—HRAS—urinary bladder cancer	8.84e-06	4.3e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	8.8e-06	4.28e-05	CbGpPWpGaD
Theophylline—ADORA2A—Signaling Pathways—MYC—urinary bladder cancer	8.79e-06	4.28e-05	CbGpPWpGaD
Theophylline—HDAC2—Signaling Pathways—KRAS—urinary bladder cancer	8.74e-06	4.25e-05	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	8.65e-06	4.21e-05	CbGpPWpGaD
Theophylline—ADORA2A—Signaling Pathways—EGFR—urinary bladder cancer	8.6e-06	4.18e-05	CbGpPWpGaD
Theophylline—CYP2D6—Metabolism—TYMS—urinary bladder cancer	8.53e-06	4.15e-05	CbGpPWpGaD
Theophylline—CYP1B1—Metabolism—EP300—urinary bladder cancer	8.53e-06	4.15e-05	CbGpPWpGaD
Theophylline—CYP2E1—Metabolism—PPARG—urinary bladder cancer	8.51e-06	4.14e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism—TYMS—urinary bladder cancer	8.45e-06	4.11e-05	CbGpPWpGaD
Theophylline—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	8.43e-06	4.1e-05	CbGpPWpGaD
Theophylline—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	8.43e-06	4.1e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	8.36e-06	4.07e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	8.36e-06	4.07e-05	CbGpPWpGaD
Theophylline—CYP2E1—Metabolism—CREBBP—urinary bladder cancer	8.18e-06	3.98e-05	CbGpPWpGaD
Theophylline—ADORA2A—Signaling Pathways—KRAS—urinary bladder cancer	8.12e-06	3.95e-05	CbGpPWpGaD
Theophylline—CYP2D6—Metabolism—GPX1—urinary bladder cancer	8.07e-06	3.93e-05	CbGpPWpGaD
Theophylline—CYP1A1—Metabolism—PPARG—urinary bladder cancer	8.03e-06	3.91e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism—GPX1—urinary bladder cancer	8e-06	3.89e-05	CbGpPWpGaD
Theophylline—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	7.93e-06	3.86e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	7.88e-06	3.84e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	7.86e-06	3.82e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	7.77e-06	3.78e-05	CbGpPWpGaD
Theophylline—HDAC2—Signaling Pathways—TP53—urinary bladder cancer	7.77e-06	3.78e-05	CbGpPWpGaD
Theophylline—CYP1A1—Metabolism—CREBBP—urinary bladder cancer	7.71e-06	3.75e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	7.52e-06	3.66e-05	CbGpPWpGaD
Theophylline—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	7.45e-06	3.63e-05	CbGpPWpGaD
Theophylline—HDAC2—Signaling Pathways—HRAS—urinary bladder cancer	7.43e-06	3.61e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	7.39e-06	3.59e-05	CbGpPWpGaD
Theophylline—CYP2C8—Metabolism—PPARG—urinary bladder cancer	7.36e-06	3.58e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism—TYMS—urinary bladder cancer	7.22e-06	3.52e-05	CbGpPWpGaD
Theophylline—ADORA2A—Signaling Pathways—TP53—urinary bladder cancer	7.22e-06	3.51e-05	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—NQO1—urinary bladder cancer	7.19e-06	3.5e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	7.14e-06	3.48e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	7.14e-06	3.48e-05	CbGpPWpGaD
Theophylline—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	7.07e-06	3.44e-05	CbGpPWpGaD
Theophylline—ADORA2A—Signaling Pathways—HRAS—urinary bladder cancer	6.9e-06	3.36e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism—GPX1—urinary bladder cancer	6.84e-06	3.33e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	6.71e-06	3.27e-05	CbGpPWpGaD
Theophylline—CYP2E1—Metabolism—PTGS2—urinary bladder cancer	6.7e-06	3.26e-05	CbGpPWpGaD
Theophylline—CYP1A1—Metabolism—PTGS2—urinary bladder cancer	6.31e-06	3.07e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	6.31e-06	3.07e-05	CbGpPWpGaD
Theophylline—CYP2D6—Metabolism—PPARG—urinary bladder cancer	6.04e-06	2.94e-05	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	6e-06	2.92e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism—PPARG—urinary bladder cancer	5.99e-06	2.91e-05	CbGpPWpGaD
Theophylline—CYP2E1—Metabolism—PTEN—urinary bladder cancer	5.84e-06	2.84e-05	CbGpPWpGaD
Theophylline—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	5.8e-06	2.82e-05	CbGpPWpGaD
Theophylline—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	5.79e-06	2.82e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	5.75e-06	2.8e-05	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—TYMS—urinary bladder cancer	5.58e-06	2.71e-05	CbGpPWpGaD
Theophylline—CYP2E1—Metabolism—EP300—urinary bladder cancer	5.57e-06	2.71e-05	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	5.51e-06	2.68e-05	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	5.51e-06	2.68e-05	CbGpPWpGaD
Theophylline—CYP1A1—Metabolism—PTEN—urinary bladder cancer	5.51e-06	2.68e-05	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—GPX1—urinary bladder cancer	5.28e-06	2.57e-05	CbGpPWpGaD
Theophylline—CYP1A1—Metabolism—EP300—urinary bladder cancer	5.25e-06	2.56e-05	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	5.18e-06	2.52e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism—PPARG—urinary bladder cancer	5.12e-06	2.49e-05	CbGpPWpGaD
Theophylline—CYP2C8—Metabolism—PTEN—urinary bladder cancer	5.05e-06	2.46e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	4.92e-06	2.39e-05	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	4.87e-06	2.37e-05	CbGpPWpGaD
Theophylline—CYP2C8—Metabolism—EP300—urinary bladder cancer	4.81e-06	2.34e-05	CbGpPWpGaD
Theophylline—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	4.75e-06	2.31e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	4.71e-06	2.29e-05	CbGpPWpGaD
Theophylline—CYP2D6—Metabolism—PTEN—urinary bladder cancer	4.14e-06	2.02e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism—PTEN—urinary bladder cancer	4.11e-06	2e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	4.03e-06	1.96e-05	CbGpPWpGaD
Theophylline—CYP2D6—Metabolism—EP300—urinary bladder cancer	3.95e-06	1.92e-05	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—PPARG—urinary bladder cancer	3.95e-06	1.92e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism—EP300—urinary bladder cancer	3.92e-06	1.91e-05	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	3.79e-06	1.85e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism—PTEN—urinary bladder cancer	3.51e-06	1.71e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism—EP300—urinary bladder cancer	3.35e-06	1.63e-05	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	3.11e-06	1.51e-05	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—PTEN—urinary bladder cancer	2.71e-06	1.32e-05	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—EP300—urinary bladder cancer	2.58e-06	1.26e-05	CbGpPWpGaD
